Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 4

2(50.0%)

4Total

Phase 3(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06054880Phase 4Recruiting

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

Role: lead

NCT06085183Phase 4Recruiting

Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment

Role: lead

NCT06448143Phase 3Not Yet Recruiting

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients

Role: lead

NCT03542760Completed

Acquired Methemoglobinemia Observational Registry

Role: collaborator

NCT04228445Phase 3Completed

3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency

Role: lead

All 5 trials loaded